TFF Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results
07 mars 2023 16h15 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, March 07, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
TFF Pharmaceuticals to Participate in the 35th Annual Roth Conference
06 mars 2023 16h05 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, March 06, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer
08 févr. 2023 16h05 HE
|
TFF Pharmaceuticals, Inc.
Dr. Harlan Weisman and recently appointed Chief Medical Officer Dr. Zamaneh Mikhak to Provide an Overview of the Corporate Strategy and 2023 Objectives Conference Call and Webcast Scheduled for...
TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer
09 janv. 2023 08h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Announces Leadership Transition
05 déc. 2022 06h30 HE
|
TFF Pharmaceuticals, Inc.
Glenn Mattes to step down as Chief Executive Officer and as a Member of the Board of Directors Dr. Harlan F. Weisman, Vice Chairman of the Board, appointed as Interim Chief Executive Officer ...
TFF Pharmaceuticals Announces Closing of $12.3 Million Public Offering
29 nov. 2022 16h01 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants
18 nov. 2022 08h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
17 nov. 2022 16h01 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 17, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
14 nov. 2022 16h01 HE
|
TFF Pharmaceuticals, Inc.
Clinical Proof-of-Concept Demonstrated in Compassionate Use in Two Case Studies with Voriconazole Inhalation Powder (TFF VORI) Growing Body of Peer-Reviewed Scientific Literature Provides...
TFF Pharmaceuticals to Hold Third Quarter 2022 Financial and Business Results Conference Call on November 14, 2022
07 nov. 2022 16h05 HE
|
TFF Pharmaceuticals, Inc.
Company conference call and webcast at 4:30 PM ET FORT WORTH, Texas, Nov. 07, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused...